ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature.

Jordan E Vellky Brenna J Kirkpatrick Lisa C Gutgesell Mathias Morales Ryan M Brown Yaqi Wu Mark G Maienschein-Cline Lucia D Notardonato Michael S Weinfeld Ryan H Nguyen Eileen Brister Maria Sverdlov Li Liu Ziqiao Xu Steven Kregel Larisa Nonn Donald J Vander Griend Natalie M Reizine

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

In diverse CSPC patient populations, ERBB3 OE was associated with high AR signaling despite low intraprostatic androgen. Mechanistic studies demonstrated a direct link between HER3 and enzalutamide resistance. ERBB3 OE as a biomarker could thus stratify patients for intensification of therapy in castration-sensitive disease, including targeting HER3 directly to improve sensitivity to AR-targeted therapies.

Keyphrases

prostate cancer
tyrosine kinase
end stage renal disease
newly diagnosed
ejection fraction
radical prostatectomy
chronic kidney disease
prognostic factors
cell proliferation
transcription factor
peritoneal dialysis
patient reported outcomes
drug delivery